https://orcid.org/0000-0002-4170-0105
Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kang Zhang, Meng-di Wang, Shang-shang Jiang, Long Tang, Yue-fen Wang, Yuan Meng, Zhen Cai, Xue-yan Sun, Fang-qiang Cui & Wen-jing Zhao. (2023) Is serum hemoglobin level an independent prognostic factor for IgA nephropathy?: a systematic review and meta-analysis of observational cohort studies. Renal Failure 45:1.
Read now
Read now
Changxiu Miao, Xiaoyu Zhu, Xuejiao Wei, Mengtuan Long, Lili Jiang, Chenhao Li, Die Jin & Yujun Du. (2022) Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases. Renal Failure 44:1, pages 881-892.
Read now
Read now
Articles from other publishers (14)
Xiaoe You, Baochun Guo, Zhen Wang, Hualin Ma, Lixia Liu, Ru Zhou, Yaxuan Zheng & Xinzhou Zhang. (2023) Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat. Molecular Omics 19:6, pages 473-483.
Crossref
Crossref
Amelia T. Davies, Paula M. Devlin, Cory Dugan, Toby Richards & Lachlan F. Miles. (2023) Non‐erythropoiesis stimulating agent, non‐iron therapies for the management of anemia: A scoping review. Transfusion 63:4, pages 849-860.
Crossref
Crossref
Yoshitada Hoshino, Masayuki OsawaEmi FunayamaKosuke Ishikawa, Takahiro Miura, Masahiro HojoYuhei YamamotoTaku Maeda. (2023) Therapeutic Potential of the Prolyl Hydroxylase Inhibitor Roxadustat in a Mouse Hindlimb Lymphedema Model. Lymphatic Research and Biology.
Crossref
Crossref
Jie Pan, Jing Zhao, Ling Feng, Xiaoli Xu, Zhiting He & Wei Liang. (2022) Inhibition of USP14 Suppresses ROS-dependent Ferroptosis and Alleviates Renal Ischemia/Reperfusion Injury. Cell Biochemistry and Biophysics 81:1, pages 87-96.
Crossref
Crossref
Tingting Fang, Congcong Ma, Zhanming Zhang, Luning Sun & Ningning Zheng. (2023) Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications. Frontiers in Pharmacology 14.
Crossref
Crossref
Dai-gang Yang, Yong-yao Gao, Ze-qun Yin, Xue-rui Wang, Xian-she Meng, Ting-feng Zou, Ya-jun Duan, Yuan-li Chen, Chen-zhong Liao, Zhou-ling Xie, Xiao-dong Fan, Lu Sun, Ji-hong Han & Xiao-xiao Yang. (2022) Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway. Acta Pharmacologica Sinica 44:2, pages 308-320.
Crossref
Crossref
Mehmet Kanbay, Alara Altıntas, Furkan Yavuz, Sidar Copur, Laura G. Sanchez-Lozada, Miguel A. Lanaspa & Richard J. Johnson. (2023) Responses to Hypoxia: How Fructose Metabolism and Hypoxia-Inducible Factor-1a Pathways Converge in Health and Disease. Current Nutrition Reports 12:1, pages 181-190.
Crossref
Crossref
Juanjuan Lei, Han Li & Shixiang Wang. (2022) Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients. BioMed Research International 2022, pages 1-12.
Crossref
Crossref
Jun-Li Tsai, Cheng-Hsu Chen, Ming-Ju Wu & Shang-Feng Tsai. (2022) New Approaches to Diabetic Nephropathy from Bed to Bench. Biomedicines 10:4, pages 876.
Crossref
Crossref
Mengqiu Miao, Mengqiu Wu, Yuting Li, Lingge Zhang, Qianqian Jin, Jiaojiao Fan, Xinyue Xu, Ran Gu, Haiping Hao, Aihua Zhang & Zhanjun Jia. (2022) Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases. Frontiers in Pharmacology 13.
Crossref
Crossref
Mei Zhang, Rong Dong, Jing Yuan, Jingjing Da, Yan Zha & Yanjun Long. (2021) Roxadustat (FG‐4592) protects against ischaemia/reperfusion‐induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice. Clinical and Experimental Pharmacology and Physiology 49:2, pages 311-318.
Crossref
Crossref
Gdayllon Cavalcante Meneses, Ranieri Sales de Souza Santos, Alice Maria Costa Martins & Elizabeth De Francesco Daher. 2022. Innovations in Nephrology. Innovations in Nephrology
127
140
.
Dengpiao Xie, Juan Wang, Gaizun Hu, Chaoling Chen, Hu Yang, Joseph K. Ritter, Yun Qu & Ningjun Li. (2021) Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury. Journal of Pharmacology and Experimental Therapeutics 378:3, pages 235-243.
Crossref
Crossref
Mengqiu Wu, Weiyi Chen, Mengqiu Miao, Qianqian Jin, Shengnan Zhang, Mi Bai, Jiaojiao Fan, Yue Zhang, Aihua Zhang, Zhanjun Jia & Songming Huang. (2021) Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. Clinical Science 135:14, pages 1707-1726.
Crossref
Crossref